pharmaceutical product evaluation, research and development services, namely identifying alternative indications, doses, or patient populations for a compound that has failed, stalled or been deprioritized so it can be redirected back into clinical development

'altern':10 'back':31 'clinic':33 'compound':18 'depriorit':25 'develop':6,34 'dose':12 'evalu':3 'fail':21 'identifi':9 'indic':11 'name':8 'patient':14 'pharmaceut':1 'popul':15 'product':2 'redirect':30 'research':4 'servic':7 'stall':22

PHASE R

Owners

Goods & Services